The skin study reportedly suggested that the company’s collagen ingredient stimulated dermal fibroblasts, which are responsible for primarily collagen types I and III production.
According to the company, removing the ‘II’ “turns the page on the first chapter of BioCell Collagen, one in which the focus was purely related to joint health, into a new era of looking to the ingredient as the answer for comprehensive connective tissue health”.
“The recently completed human skin study on BioCell Collagen showed a significant increase in collagen content in the skin dermis,” said Dr Joosang Park, VP of scientific affairs at the BioCell.
“ This and earlier studies demonstrate the unique biological properties of BioCell Collagen to support the dermal matrix containing collagen types I and III as well as the cartilage containing type II.”